|
Iressa/Docetaxel in Non-Small-Cell Lung Cancer Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Iressa/Docetaxel in Non-Small-Cell Lung Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Iressa/Docetaxel in Non-Small-Cell Lung Cancer Clinical research trials and Iressa/Docetaxel in Non-Small-Cell Lung Cancer healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Iressa/Docetaxel in Non-Small-Cell Lung Cancer. Iressa/Docetaxel in Non-Small-Cell Lung Cancer Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Iressa/Docetaxel in Non-Small-Cell Lung Cancer clinical trial. Subjects frequently obtain the most expert healthcare possible for their Iressa/Docetaxel in Non-Small-Cell Lung Cancer condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Iressa/Docetaxel in Non-Small-Cell Lung Cancer  Iressa/Docetaxel in Non-Small-Cell Lung Cancer
Iressa/Docetaxel in Non-Small-Cell Lung Cancer
For Condition: Non-small cell lung cancer
Status: Terminated
Sponsor(s): M.D. Anderson Cancer Center , AstraZeneca,Aventis Pharmaceuticals
Synopsis: Patients will receive 250 mg Iressa by mouth daily each day while on this study. Patients will also receive docetaxel 30 mg/m2 by IV on day 1 weekly for the first 3 weeks of each course of therapy. A course of therapy is 4 weeks. Patients will not receive docetaxel during week 4. A maximum of 8 full cycles of docetaxel plus Iressa are planned. Patients may continue on daily Iressa until progressive disease and/or unacceptable toxicity.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Inclusion: - Pathologically confirmed non-small cell lung cancer. - Measurable, evaluable disease outside of a radiation port. - ECOG performance status 0-2. - Adequate hematologic function as defined by an absolute neutrophil count >= 1,500/mm3, a platelet count >= 100,000/mm3, a WBC >= 3,000/ mm3, and a hemoglobin level of >= 9 g/dl. - One prior chemotherapy regimen. This may include chemoradiation treatment. - Disease progression or recurrence within 6 months of last dose of chemotherapy in first chemotherapy regimen. - At least a 2-week recovery from prior therapy toxicity. - Signed informed consent. - Prior CNS involvement by tumor are eligible if previously treated and clinically stable for two weeks after completion of treatment. Exclusion: - Prior Iressa or other EGFR inhibiting agents - Prior docetaxel therapy - Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ. - Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy. - Incomplete healing from previous oncologic or other major surgery. - Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, St John's Wort, anti-coagulants. - Absolute neutrophil counts less than 1500 x 109/liter (L) or platelets less than 100,000x 109/liter (L). - Serum bilirubin greater than 1.25 times the upper limit of reference range (ULRR). - In the opinion of the investigator, any evidence of severe or uncontrolled systemic disease, (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease). - A serum creatinine >= 1.5 mg/dl and calculated creatinine clearance <= 60 cc/minute. - Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2.5 times the ULRR if no demonstrable liver metastases or greater than 5 times the ULRR in the presence of liver metastases. - Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial. - Pregnancy or breast feeding - The patient has uncontrolled seizure disorder, active neurological disease, or Grade >= 2 neuropathy - The patient has received any investigational agent(s) within 30 days of study entry. - The patient has signs and symptoms of keratoconjunctivitis sicca or incompletely treated eye infection.
Total Enrollment: 50
Location and Contact Information:
Additional Information:
Study ID Numbers: ID02-004;
Study Start Date: August 2002
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00048087
Other Non-Small Cell Lung Cancer Studies:
1. KRN7000 in Treating Patients With Solid Tumors
2. Vaccine Therapy in Treating Patients With Gastric Cancer, Non-Small Cell Lung Cancer, Prostate, or Ovarian Cancer
3. Phase III Randomized Study of Nicotine Inhaler Versus Bupropion Versus Nicotine Inhaler Plus Bupropion for Smoking Cessation and Prevention of Relapse in Participants Who Currently Smoke
4. BB-10901 in Treating Patients With Recurrent or Refractory Lung Cancer, Metastatic Carcinoid Tumor, or Other Solid Tumors
5. Combination Chemotherapy Treatment For Advanced Non-Small Cell Lung Cancer Patients Having Prior Chemotherapy
Related Studies:
Other Non-small cell lung cancer Clinical Trials
Other Clinical Trials
Other Clinical Trials
Iressa/Docetaxel in Non-Small-Cell Lung Cancer
|
|
|
|
|
|
|
|
